1
|
Benedetti E, Micouin L. Have spirocyclic scaffolds been properly utilized in recent drug discovery efforts? Expert Opin Drug Discov 2024; 19:263-266. [PMID: 38225892 DOI: 10.1080/17460441.2024.2305735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2023] [Accepted: 01/11/2024] [Indexed: 01/17/2024]
Affiliation(s)
| | - Laurent Micouin
- Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, Université Paris Cité, CNRS, Paris, France
| |
Collapse
|
2
|
Espinoza-Chávez RM, Oliveira Rezende Júnior CD, de Souza ML, Pauli I, Valli M, Gomes Ferreira LL, Chelucci RC, Michelan-Duarte S, Krogh R, Romualdo da Silva FB, Cruz FC, de Oliveira AS, Andricopulo AD, Dias LC. Structure-activity relationships of novel N-imidazoylpiperazines with potent anti- Trypanosoma cruzi activity. Future Med Chem 2024; 16:253-269. [PMID: 38193294 DOI: 10.4155/fmc-2023-0185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2023] [Accepted: 12/06/2023] [Indexed: 01/10/2024] Open
Abstract
Background: Chagas disease is caused by the parasite Trypanosoma cruzi, and the lack of effective and safe treatments makes identifying new classes of compounds with anti-T. cruzi activity of paramount importance. Methods: Hit-to-lead exploration of a metabolically stable N-imidazoylpiperazine was performed. Results: Compound 2, a piperazine derivative active against T. cruzi, was selected to perform the hit-to-lead exploration, which involved the design, synthesis and biological evaluation of 39 new derivatives. Conclusion: Compounds 6e and 10a were identified as optimized compounds with low micromolar in vitro activity, low cytotoxicity and suitable preliminary absorption, distribution, metabolism and excretion and physicochemical properties. Both compounds reduced parasitemia in mouse models of Chagas disease, providing a promising opportunity for further exploration of new antichagasic compounds.
Collapse
Affiliation(s)
- Rocío Marisol Espinoza-Chávez
- Laboratory of Synthetic Organic Chemistry, Institute of Chemistry, State University of Campinas, Campinas-SP, 13084-971, Brazil
| | - Celso de Oliveira Rezende Júnior
- Laboratory of Synthetic Organic Chemistry, Institute of Chemistry, State University of Campinas, Campinas-SP, 13084-971, Brazil
- Institute of Chemistry, Federal University of Uberlândia, Uberlândia-MG, 38400-902, Brazil
| | - Mariana Laureano de Souza
- Laboratory of Medicinal & Computational Chemistry, São Carlos Institute of Physics, University of São Paulo, São Carlos-SP, 13563-120, Brazil
| | - Ivani Pauli
- Laboratory of Medicinal & Computational Chemistry, São Carlos Institute of Physics, University of São Paulo, São Carlos-SP, 13563-120, Brazil
| | - Marilia Valli
- Laboratory of Medicinal & Computational Chemistry, São Carlos Institute of Physics, University of São Paulo, São Carlos-SP, 13563-120, Brazil
| | - Leonardo Luiz Gomes Ferreira
- Laboratory of Medicinal & Computational Chemistry, São Carlos Institute of Physics, University of São Paulo, São Carlos-SP, 13563-120, Brazil
| | - Rafael Consolin Chelucci
- Laboratory of Medicinal & Computational Chemistry, São Carlos Institute of Physics, University of São Paulo, São Carlos-SP, 13563-120, Brazil
| | - Simone Michelan-Duarte
- Laboratory of Medicinal & Computational Chemistry, São Carlos Institute of Physics, University of São Paulo, São Carlos-SP, 13563-120, Brazil
| | - Renata Krogh
- Laboratory of Medicinal & Computational Chemistry, São Carlos Institute of Physics, University of São Paulo, São Carlos-SP, 13563-120, Brazil
| | | | - Fábio Cardoso Cruz
- Department of Pharmacology, Federal University of São Paulo - UNIFESP, São Paulo-SP, 04023-062, Brazil
| | - Aldo Sena de Oliveira
- Department of Exact Sciences & Education, Federal University of Santa Catarina, Campus of Blumenau, Santa Catarina-SC, 89036-256, Brazil
| | - Adriano Defini Andricopulo
- Laboratory of Medicinal & Computational Chemistry, São Carlos Institute of Physics, University of São Paulo, São Carlos-SP, 13563-120, Brazil
| | - Luiz Carlos Dias
- Laboratory of Synthetic Organic Chemistry, Institute of Chemistry, State University of Campinas, Campinas-SP, 13084-971, Brazil
| |
Collapse
|
3
|
Ni T, Xie F, Li L, Hao Y, Chi X, Yan L, Zhang D, Jiang Y, Lv Q. Design, Synthesis and Structure-Activity Relationship Studies of Nicotinamide Derivatives as Potent Antifungal Agents by Disrupting Cell Wall. Molecules 2023; 28. [PMID: 36770802 DOI: 10.3390/molecules28031135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2022] [Revised: 01/16/2023] [Accepted: 01/20/2023] [Indexed: 01/25/2023] Open
Abstract
Fungal infections pose a serious challenge to human health due to the limited paucity of antifungal treatments. Starting as a hit compound screened from our compound library, a series of nicotinamide derivatives have been successfully synthesized via a facile one-step coupling reaction of aromatic carboxylic acid and amine. The synthesized compounds were evaluated for their antifungal activity against Candida albicans SC5314. Among the 37 nicotinamide derivatives screened, compound 16g was found to be the most active against C. albicans SC5314, with an MIC value of 0.25 μg/mL and without significant cytotoxicity. The rudimentary structure-activity relationships study revealed that the position of the amino and isopropyl groups of 16g was critical for its antifungal activity. In particular, compound 16g showed potent activity against six fluconazole-resistant C. albicans strains with MIC values ranging from 0.125-1 μg/mL and showed moderate activity against the other seven species of Candida, three strains of Cryptococcus neoformans, and three strains of Trichophyton. Furthermore, compound 16g showed fungicidal, anti-hyphal, and anti-biofilm activities in vitro, which were related to its ability to disrupt the cell wall of C. albicans. Taken together, 16g is a promising compound that is fungal-specific by targeting the cell wall and could be used as a lead compound for further investigation.
Collapse
|
4
|
Alshiraihi IM, Jarrell DK, Arhouma Z, Hassell KN, Montgomery J, Padilla A, Ibrahim HM, Crans DC, Kato TA, Brown MA. In Silico/In Vitro Hit-to-Lead Methodology Yields SMYD3 Inhibitor That Eliminates Unrestrained Proliferation of Breast Carcinoma Cells. Int J Mol Sci 2020; 21:ijms21249549. [PMID: 33333978 PMCID: PMC7765450 DOI: 10.3390/ijms21249549] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2020] [Revised: 12/10/2020] [Accepted: 12/11/2020] [Indexed: 12/29/2022] Open
Abstract
SMYD3 is a lysine methyltransferase that regulates the expression of over 80 genes and is required for the uncontrolled proliferation of most breast, colorectal, and hepatocellular carcinomas. The elimination of SMYD3 restores normal expression patterns of these genes and halts aberrant cell proliferation, making it a promising target for small molecule inhibition. In this study, we sought to establish a proof of concept for our in silico/in vitro hit-to-lead enzyme inhibitor development platform and to identify a lead small molecule candidate for SMYD3 inhibition. We used Schrodinger® software to screen libraries of small molecules in silico and the five compounds with the greatest predicted binding affinity within the SMYD3 binding pocket were purchased and assessed in vitro in direct binding assays and in breast cancer cell lines. We have confirmed the ability of one of these inhibitors, Inhibitor-4, to restore normal rates of cell proliferation, arrest the cell cycle, and induce apoptosis in breast cancer cells without affecting wildtype cell behavior. Our results provide a proof of concept for this fast and affordable small molecule hit-to-lead methodology as well as a promising candidate small molecule SMYD3 inhibitor for the treatment of human cancer.
Collapse
Affiliation(s)
- Ilham M. Alshiraihi
- Cell and Molecular Biology Program, Colorado State University, Fort Collins, CO 80523-1005, USA; (I.M.A.); (Z.A.); (K.N.H.); (D.C.C.); (T.A.K.)
- Department of Biology, University of Tabuk, Tabuk 47713, Saudi Arabia
| | - Dillon K. Jarrell
- Department of Bioengineering, University of Colorado Anschutz Medical Campus, Aurora, CO 80045-7109, USA;
| | - Zeyad Arhouma
- Cell and Molecular Biology Program, Colorado State University, Fort Collins, CO 80523-1005, USA; (I.M.A.); (Z.A.); (K.N.H.); (D.C.C.); (T.A.K.)
- Department of Chemistry, Colorado State University, Fort Collins, CO 80523-1872, USA
| | - Kelly N. Hassell
- Cell and Molecular Biology Program, Colorado State University, Fort Collins, CO 80523-1005, USA; (I.M.A.); (Z.A.); (K.N.H.); (D.C.C.); (T.A.K.)
| | - Jaelyn Montgomery
- Department of Biomedical Sciences, Colorado State University, Fort Collins, CO 80523-1617, USA; (J.M.); (A.P.)
| | - Alyssa Padilla
- Department of Biomedical Sciences, Colorado State University, Fort Collins, CO 80523-1617, USA; (J.M.); (A.P.)
| | - Hend M. Ibrahim
- Department of Medical Biochemistry, Zagazig University, Zagazig 44511, Egypt;
- Department of Environmental & Radiological Health Sciences, Colorado State University, Fort Collins, CO 80523-1618, USA
- Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523-1678, USA
| | - Debbie C. Crans
- Cell and Molecular Biology Program, Colorado State University, Fort Collins, CO 80523-1005, USA; (I.M.A.); (Z.A.); (K.N.H.); (D.C.C.); (T.A.K.)
- Department of Chemistry, Colorado State University, Fort Collins, CO 80523-1872, USA
| | - Takamitsu A. Kato
- Cell and Molecular Biology Program, Colorado State University, Fort Collins, CO 80523-1005, USA; (I.M.A.); (Z.A.); (K.N.H.); (D.C.C.); (T.A.K.)
- Department of Environmental & Radiological Health Sciences, Colorado State University, Fort Collins, CO 80523-1618, USA
| | - Mark A. Brown
- Cell and Molecular Biology Program, Colorado State University, Fort Collins, CO 80523-1005, USA; (I.M.A.); (Z.A.); (K.N.H.); (D.C.C.); (T.A.K.)
- Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523-1678, USA
- Epidemiology Section, Colorado School of Public Health, Fort Collins, CO 80523-1612, USA
- Institute for Learning and Teaching, Colorado State University, Fort Collins, CO 80523-1052, USA
- Department of Ethnic Studies, Colorado State University, Fort Collins, CO 80523-1790, USA
- Correspondence:
| |
Collapse
|
5
|
Pestana-Nobles R, Leyva-Rojas JA, Yosa J. Searching Hit Potential Antimicrobials in Natural Compounds Space against Biofilm Formation. Molecules 2020; 25:E5334. [PMID: 33207596 PMCID: PMC7696173 DOI: 10.3390/molecules25225334] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2020] [Revised: 10/10/2020] [Accepted: 10/20/2020] [Indexed: 01/06/2023] Open
Abstract
Biofilms are communities of microorganisms that can colonize biotic and abiotic surfaces and thus play a significant role in the persistence of bacterial infection and resistance to antimicrobial. About 65% and 80% of microbial and chronic infections are associated with biofilm formation, respectively. The increase in infections by multi-resistant bacteria instigates the need for the discovery of novel natural-based drugs that act as inhibitory molecules. The inhibition of diguanylate cyclases (DGCs), the enzyme implicated in the synthesis of the second messenger, cyclic diguanylate (c-di-GMP), involved in the biofilm formation, represents a potential approach for preventing the biofilm development. It has been extensively studied using PleD protein as a model of DGC for in silico studies as virtual screening and as a model for in vitro studies in biofilms formation. This study aimed to search for natural products capable of inhibiting the Caulobacter crescentus enzyme PleD. For this purpose, 224,205 molecules from the natural products ZINC15 database, have been evaluated through molecular docking and molecular dynamic simulation. Our results suggest trans-Aconitic acid (TAA) as a possible starting point for hit-to-lead methodologies to obtain new inhibitors of the PleD protein and hence blocking the biofilm formation.
Collapse
|
6
|
Bruno A, Costantino G, Sartori L, Radi M. The In Silico Drug Discovery Toolbox: Applications in Lead Discovery and Optimization. Curr Med Chem 2019; 26:3838-3873. [PMID: 29110597 DOI: 10.2174/0929867324666171107101035] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2017] [Revised: 09/27/2017] [Accepted: 09/28/2017] [Indexed: 01/04/2023]
Abstract
BACKGROUND Discovery and development of a new drug is a long lasting and expensive journey that takes around 20 years from starting idea to approval and marketing of new medication. Despite R&D expenditures have been constantly increasing in the last few years, the number of new drugs introduced into market has been steadily declining. This is mainly due to preclinical and clinical safety issues, which still represent about 40% of drug discontinuation. To cope with this issue, a number of in silico techniques are currently being used for an early stage evaluation/prediction of potential safety issues, allowing to increase the drug-discovery success rate and reduce costs associated with the development of a new drug. METHODS In the present review, we will analyse the early steps of the drug-discovery pipeline, describing the sequence of steps from disease selection to lead optimization and focusing on the most common in silico tools used to assess attrition risks and build a mitigation plan. RESULTS A comprehensive list of widely used in silico tools, databases, and public initiatives that can be effectively implemented and used in the drug discovery pipeline has been provided. A few examples of how these tools can be problem-solving and how they may increase the success rate of a drug discovery and development program have been also provided. Finally, selected examples where the application of in silico tools had effectively contributed to the development of marketed drugs or clinical candidates will be given. CONCLUSION The in silico toolbox finds great application in every step of early drug discovery: (i) target identification and validation; (ii) hit identification; (iii) hit-to-lead; and (iv) lead optimization. Each of these steps has been described in details, providing a useful overview on the role played by in silico tools in the decision-making process to speed-up the discovery of new drugs.
Collapse
Affiliation(s)
- Agostino Bruno
- Experimental Therapeutics Unit, IFOM - The FIRC Institute for Molecular Oncology Foundation, Via Adamello 16 - 20139 Milano, Italy
| | - Gabriele Costantino
- Dipartimento di Scienze degli Alimenti e del Farmaco, Universita degli Studi di Parma, Viale delle Scienze, 27/A, 43124 Parma, Italy
| | - Luca Sartori
- Experimental Therapeutics Unit, IFOM - The FIRC Institute for Molecular Oncology Foundation, Via Adamello 16 - 20139 Milano, Italy
| | - Marco Radi
- Dipartimento di Scienze degli Alimenti e del Farmaco, Universita degli Studi di Parma, Viale delle Scienze, 27/A, 43124 Parma, Italy
| |
Collapse
|
7
|
Längle D, Werner TR, Wesseler F, Reckzeh E, Schaumann N, Drowley L, Polla M, Plowright AT, Hirt MN, Eschenhagen T, Schade D. Toward Second-Generation Cardiomyogenic and Anti-cardiofibrotic 1,4-Dihydropyridine-Class TGFβ Inhibitors. ChemMedChem 2019; 14:810-822. [PMID: 30768867 DOI: 10.1002/cmdc.201900036] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2019] [Revised: 02/11/2019] [Indexed: 01/14/2023]
Abstract
Innovative therapeutic modalities for pharmacological intervention of transforming growth factor β (TGFβ)-dependent diseases are of great value. b-Annelated 1,4-dihydropyridines (DHPs) might be such a class, as they induce TGFβ receptor type II degradation. However, intrinsic drawbacks are associated with this compound class and were systematically addressed in the presented study. It was possible to install polar functionalities and bioisosteric moieties at distinct sites of the molecules while maintaining TGFβ-inhibitory activities. The introduction of a 2-amino group or 7-N-alkyl modification proved to be successful strategies. Aqueous solubility was improved by up to seven-fold at pH 7.4 and 200-fold at pH 3 relative to the parent ethyl 4-(biphenyl-4-yl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate. The therapeutic potential of the presented DHPs was further underscored in view of a potential dual mode of action: The differentiation of committed human iPSC-derived cardiac progenitor cells (CPCs) was potently stimulated, and the rescue of cardiac fibrosis phenotypes was observed in engineered heart tissue (EHT) constructs.
Collapse
Affiliation(s)
- Daniel Längle
- Department of Chemistry and Chemical Biology, Technische Universität Dortmund, Otto-Hahn-Str. 4, 44227, Dortmund, Germany.,Department of Pharmaceutical and Medicinal Chemistry, Christian-Albrechts-Universität Kiel, Gutenbergstr. 76, 24118, Kiel, Germany
| | - Tessa R Werner
- Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Fabian Wesseler
- Department of Chemistry and Chemical Biology, Technische Universität Dortmund, Otto-Hahn-Str. 4, 44227, Dortmund, Germany
| | - Elena Reckzeh
- Department of Chemistry and Chemical Biology, Technische Universität Dortmund, Otto-Hahn-Str. 4, 44227, Dortmund, Germany
| | - Niklas Schaumann
- Department of Chemistry and Chemical Biology, Technische Universität Dortmund, Otto-Hahn-Str. 4, 44227, Dortmund, Germany
| | - Lauren Drowley
- Cardiovascular, Renal and Metabolic Diseases IMED Biotech Unit, AstraZeneca Gothenburg, Pepparsleden 1, 43 183, Mölndal, Sweden
| | - Magnus Polla
- Cardiovascular, Renal and Metabolic Diseases IMED Biotech Unit, AstraZeneca Gothenburg, Pepparsleden 1, 43 183, Mölndal, Sweden
| | - Alleyn T Plowright
- Cardiovascular, Renal and Metabolic Diseases IMED Biotech Unit, AstraZeneca Gothenburg, Pepparsleden 1, 43 183, Mölndal, Sweden
| | - Marc N Hirt
- Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Thomas Eschenhagen
- Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Dennis Schade
- Department of Chemistry and Chemical Biology, Technische Universität Dortmund, Otto-Hahn-Str. 4, 44227, Dortmund, Germany.,Department of Pharmaceutical and Medicinal Chemistry, Christian-Albrechts-Universität Kiel, Gutenbergstr. 76, 24118, Kiel, Germany
| |
Collapse
|
8
|
Hoffer L, Muller C, Roche P, Morelli X. Chemistry-driven Hit-to-lead Optimization Guided by Structure-based Approaches. Mol Inform 2018; 37:e1800059. [PMID: 30051601 DOI: 10.1002/minf.201800059] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2018] [Accepted: 06/24/2018] [Indexed: 12/17/2022]
Abstract
For several decades, hit identification for drug discovery has been facilitated by developments in both fragment-based and high-throughput screening technologies. However, a major bottleneck in drug discovery projects continues to be the optimization of primary hits from screening campaigns in order to derive lead compounds. Computational chemistry or molecular modeling can play an important role during this hit-to-lead (H2L) stage by both suggesting putative optimizations and decreasing the number of compounds to be experimentally synthesized and evaluated. However, it is also crucial to consider the feasibility of organically synthesizing these virtually designed compounds. Furthermore, the generated molecules should have reasonable physicochemical properties and be medicinally relevant. This review focuses on chemistry-driven and structure-based computational methods that can be used to tackle the difficult problem of H2L optimization, with emphasis being placed on the strategy developed in our laboratory.
Collapse
Affiliation(s)
- Laurent Hoffer
- CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ, CRCM, Marseille, France
| | | | - Philippe Roche
- CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ, CRCM, Marseille, France
| | - Xavier Morelli
- CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ, CRCM, Marseille, France.,Institut Paoli-Calmettes, IPC Drug Discovery, Marseille, France
| |
Collapse
|
9
|
Lôme V, Brunel JM, Pagès JM, Bolla JM. Multiparametric Profiling for Identification of Chemosensitizers against Gram-Negative Bacteria. Front Microbiol 2018; 9:204. [PMID: 29556218 PMCID: PMC5845390 DOI: 10.3389/fmicb.2018.00204] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2017] [Accepted: 01/29/2018] [Indexed: 01/22/2023] Open
Abstract
Antibiotic resistance is now a worldwide therapeutic problem. Since the beginning of anti-infectious treatment bacteria have rapidly shown an incredible ability to develop and transfer resistance mechanisms. In the last decades, the design variation of pioneer bioactive molecules has strongly improved their activity and the pharmaceutical companies partly won the race against the clock. Since the 1980s, the new classes of antibiotics that emerged were mainly directed to Gram-positive bacteria. Thus, we are now facing to multidrug-resistant Gram-negative bacteria, with no therapeutic options to deal with them. These bacteria are mainly resistant because of their double membrane that conjointly impairs antibiotic accumulation and extrudes these molecules when entered. The main challenge is to allow antibiotics to cross the impermeable envelope and reach their targets. One promising solution would be to associate, in a combination therapy, a usual antibiotic with a non-antibiotic chemosensitizer. Nevertheless, for effective drug discovery, there is a prominent lack of tools required to understand the rules of permeation and accumulation into Gram-negative bacteria. By the use of a multidrug-resistant enterobacteria, we introduce a high-content screening procedure for chemosensitizers discovery by quantitative assessment of drug accumulation, alteration of barriers, and deduction of their activity profile. We assembled and analyzed a control chemicals library to perform the proof of concept. The analysis was based on real-time monitoring of the efflux alteration and measure of the influx increase in the presence of studied compounds in an automatized bio-assay. Then, synergistic activity of compounds with an antibiotic was studied and kinetic data reduction was performed which led to the calculation of a score for each barrier to be altered.
Collapse
Affiliation(s)
- Vincent Lôme
- UMR MD1, Aix-Marseille University, IRBA, TMCD2, Facultés de Médecine et de Pharmacie, Marseille, France
| | - Jean-Michel Brunel
- Centre de Recherche en Cancérologie de Marseille (CRCM), CNRS, UMR7258, Institut Paoli Calmettes, Aix-Marseille Université, UM 105, Inserm, U1068, Faculté de Pharmacie, Marseille, France
| | - Jean-Marie Pagès
- UMR MD1, Aix-Marseille University, IRBA, TMCD2, Facultés de Médecine et de Pharmacie, Marseille, France
| | - Jean-Michel Bolla
- UMR MD1, Aix-Marseille University, IRBA, TMCD2, Facultés de Médecine et de Pharmacie, Marseille, France
| |
Collapse
|
10
|
Abstract
Oncogenic activation of RET kinase has been found in several neoplastic diseases, like medullary thyroid carcinoma, multiple endocrine neoplasia, papillary thyroid carcinoma, and non-small-cell lung cancer. Currently approved RET inhibitors were not originally designed to be RET inhibitors, and their potency against RET kinase has not been optimized. Hence, novel compounds able to inhibit both wild-type RET (wt RET) and its mutants (e.g., V804M RET) are needed. Herein we present the development and the preliminary evaluation of a new sub-micromolar wt RET/V804M RET inhibitor, N-(2-fluoro-5-trifluoromethylphenyl)-N'-{4'-[(2''-benzamido)pyridin-4''-ylamino]phenyl}urea (69), endowed with a 4-anilinopyridine structure, starting from our previously identified 4-anilinopyrimidine hit compound. Profiling against a panel of kinases indicated 69 as a multi cKIT/wt RET/V804M RET inhibitor.
Collapse
Affiliation(s)
- Luca Mologni
- School of Medicine and Surgery, University of Milano-Bicocca, via Cadore 48, 20900, Monza, Italy
| | - Martina Dalla Via
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, via Marzolo 5, 35131, Padova, Italy
| | - Adriana Chilin
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, via Marzolo 5, 35131, Padova, Italy
| | - Manlio Palumbo
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, via Marzolo 5, 35131, Padova, Italy
| | - Giovanni Marzaro
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, via Marzolo 5, 35131, Padova, Italy
| |
Collapse
|
11
|
Hoyt SB, Petrilli W, London C, Liang GB, Tata J, Hu Q, Yin L, van Koppen CJ, Hartmann RW, Struthers M, Wisniewski T, Ren N, Bopp C, Sok A, Cai TQ, Stribling S, Pai LY, Ma X, Metzger J, Verras A, McMasters D, Chen Q, Tung E, Tang W, Salituro G, Buist N, Clemas J, Zhou G, Gibson J, Maxwell CA, Lassman M, McLaughlin T, Castro-Perez J, Szeto D, Forrest G, Hajdu R, Rosenbach M, Xiong Y. Discovery of Triazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys. ACS Med Chem Lett 2015; 6:861-5. [PMID: 26288685 DOI: 10.1021/acsmedchemlett.5b00048] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2015] [Accepted: 07/17/2015] [Indexed: 12/21/2022] Open
Abstract
Hit-to-lead efforts resulted in the discovery of compound 19, a potent CYP11B2 inhibitor that displays high selectivity vs related CYPs, good pharmacokinetic properties in rat and rhesus, and lead-like physical properties. In a rhesus pharmacodynamic model, compound 19 displays robust, dose-dependent aldosterone lowering efficacy, with no apparent effect on cortisol levels.
Collapse
Affiliation(s)
- Scott B. Hoyt
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Whitney Petrilli
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Clare London
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Gui-Bai Liang
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Jim Tata
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Qingzhong Hu
- Department
of Pharmaceutical and Medicinal Chemistry, Saarland University and Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Campus
C2-3, D-66123 Saarbrücken, Germany
| | - Lina Yin
- Department
of Pharmaceutical and Medicinal Chemistry, Saarland University and Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Campus
C2-3, D-66123 Saarbrücken, Germany
- ElexoPharm GmbH, Im Stadtwald, D-66123 Saarbrücken, Germany
| | | | - Rolf W. Hartmann
- Department
of Pharmaceutical and Medicinal Chemistry, Saarland University and Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Campus
C2-3, D-66123 Saarbrücken, Germany
| | - Mary Struthers
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Tom Wisniewski
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Ning Ren
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Charlene Bopp
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Andrea Sok
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Tian-Quan Cai
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Sloan Stribling
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Lee-Yuh Pai
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Xiuying Ma
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Joe Metzger
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Andreas Verras
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Daniel McMasters
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Qing Chen
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Elaine Tung
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Wei Tang
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Gino Salituro
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Nicole Buist
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Joe Clemas
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Gaochao Zhou
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Jack Gibson
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | | | - Mike Lassman
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | | | - Jose Castro-Perez
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Daphne Szeto
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Gail Forrest
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Richard Hajdu
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Mark Rosenbach
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Yusheng Xiong
- Merck Research Laboratories, Rahway, New Jersey 07065, United States
| |
Collapse
|